Bortezomib induces apoptosis in T-cell prolymphocytic leukemia (T-PLL) [6]

Leukemia and Lymphoma

Volumn 48, Issue 11, 2007, Pages 2247-2250

  Ozpuyan, Fulya ^a   Meyer, Paul ^a   Ni, Hongyu ^b   Al Masri, Hytham ^c   Alkan, Serhan ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b Genoptix Inc   (United States)

^c MOUNT SINAI HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 AMINO ACTINOMYCIN; AMPHOTERICIN B; BORTEZOMIB; DACTINOMYCIN; GENTAMICIN; GLUTAMINE; PENICILLIN G; PROPIDIUM IODIDE; STREPTOMYCIN; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER SURVIVAL; CASE REPORT; CELL CULTURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CRYOPRESERVATION; DRUG INHIBITION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LETTER; LEUKEMIA CELL; MICROSCOPY; MORPHOLOGY; PRIORITY JOURNAL; PROLYMPHOCYTIC LEUKEMIA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CELL SURVIVAL; CRYOPRESERVATION; DACTINOMYCIN; DRUG EVALUATION, PRECLINICAL; FLOW CYTOMETRY; HUMANS; LEUKEMIA, PROLYMPHOCYTIC, T-CELL; PYRAZINES; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 36048981351     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701636484     Document Type: Letter

References (12)

1. Gardner, R. C., Assinder, S. J., Christie, G., Mason, G. G., Markwell, R. and Wadsworth, H. (2000) Characterization of peptidyl boronic acid inhibitors of mammalian 20 S and 26 S proteasomes and their inhibition of proteasomes in cultured cells. Biochem J, 346, pp. 447-454.
2. Mitsiades, C. S., Mitsiades, N., Hideshima, T., Richardson, P. G. and Anderson, K. C. (2006) Proteasome inhibition as a new therapeutic principle in hematological malignancies. Curr Drug Targets, 7, pp. 1341-1347.
3. Ergin, M., Huang, Q., Qin, J. Z., Amin, H. M. and Martinez, R. L. (2001) Analysis of expression of nuclear factor kappa B (NF-κB) in multiple myeloma: Downregulation of NF-κB induces apoptosis. Br J Haematol, 115, pp. 279-286.
4. el'Agnaf, M. R., Ennis, K. E., Morris, T. C., Robertson, J. H., Markey, G. and Alexander, H. D. (1986) Successful remission induction with deoxycoformycin in elderly patients with T-helper prolymphocytic leukaemia. Br J Haematol, 63, pp. 93-104.
5. Mercieca, J., Matutes, E., Dearden, C., MacLennan, K. and Catovsky, D. (1994) The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. J Clin Oncol, 12, pp. 2588-2593.
6. Kipps, T. (2000) Chronic lymphocytic leukemia and related disorders. Williams Hematology, pp. 1181-1182. McGraw-Hill, New York
7. Goy, A., Younes, A., McLaughlin, P., Pro, B., Romaguera, J. E. and Hagemeister, F. (2005) Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol, 23, pp. 667-675.
8. O'Connor, O. A., Wright, J., Moskowitz, C., Muzzy, J., MacGregor-Cortelli, B. and Stubblefield, M. (2005) Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol, 23, pp. 676-684.
9. Strauss, S. J., Maharaj, L., Hoare, S., Johnson, P. W., Radford, J. A. and Vinnecombe, S. (2006) Bortezomib therapy in patients with relapsed or refractory lymphoma: Potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol, 24, pp. 2105-2112.
10. Orlowski, R. Z., Voorhees, P. M., Garcia, R. A., Hall, M. D., Kudrik, F. J. and Allred, T. (2005) Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood, 105, pp. 3058-3065.
11. Mai, W., Meng, H., Jin, J. and Wang, L. (2006) Treatment with bortezomib in a patient with heavily pretreated refractory T-cell lymphoblastic lymphoma. Eur J Haematol, 77, pp. 445-447.
12. Pahler, J. C., Ruiz, S., Niemer, I., Calvert, L. R., Andreeff, M. and Keating, M. (2003) Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia. Clin Cancer Res, 9, pp. 4570-4577.